PL3517534T3 - Związki użyteczne w leczeniu nowotworu - Google Patents
Związki użyteczne w leczeniu nowotworuInfo
- Publication number
- PL3517534T3 PL3517534T3 PL19157827.7T PL19157827T PL3517534T3 PL 3517534 T3 PL3517534 T3 PL 3517534T3 PL 19157827 T PL19157827 T PL 19157827T PL 3517534 T3 PL3517534 T3 PL 3517534T3
- Authority
- PL
- Poland
- Prior art keywords
- treating cancer
- compounds useful
- compounds
- useful
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18655209P | 2009-06-12 | 2009-06-12 | |
| US18654409P | 2009-06-12 | 2009-06-12 | |
| EP09162630A EP2261214A1 (en) | 2009-06-12 | 2009-06-12 | Compounds useful to treat premature aging and in particular progeria |
| EP20090305540 EP2266972A1 (en) | 2009-06-12 | 2009-06-12 | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3517534T3 true PL3517534T3 (pl) | 2024-06-24 |
Family
ID=43309298
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10757474.1T PL2440547T3 (pl) | 2009-06-12 | 2010-06-14 | Nowe cząsteczki chemiczne hamujące mechanizm splicingu do leczenia chorób wynikających z defektów splicingu |
| PL19157827.7T PL3517534T3 (pl) | 2009-06-12 | 2010-06-14 | Związki użyteczne w leczeniu nowotworu |
| PL10728368T PL2440545T3 (pl) | 2009-06-12 | 2010-06-14 | Związki użyteczne do leczenia nowotworu |
| PL10728369.9T PL2440546T3 (pl) | 2009-06-12 | 2010-06-14 | Związki przydatne do leczenia przedwczesnego starzenia się, a w szczególności progerii |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10757474.1T PL2440547T3 (pl) | 2009-06-12 | 2010-06-14 | Nowe cząsteczki chemiczne hamujące mechanizm splicingu do leczenia chorób wynikających z defektów splicingu |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10728368T PL2440545T3 (pl) | 2009-06-12 | 2010-06-14 | Związki użyteczne do leczenia nowotworu |
| PL10728369.9T PL2440546T3 (pl) | 2009-06-12 | 2010-06-14 | Związki przydatne do leczenia przedwczesnego starzenia się, a w szczególności progerii |
Country Status (23)
| Country | Link |
|---|---|
| US (7) | US9145367B2 (pl) |
| EP (6) | EP2440545B1 (pl) |
| JP (8) | JP6041671B2 (pl) |
| KR (14) | KR20120051643A (pl) |
| CN (13) | CN106905232B (pl) |
| AU (3) | AU2010258294B2 (pl) |
| BR (5) | BR122019013687B1 (pl) |
| CA (5) | CA2764024C (pl) |
| CU (4) | CU24124B1 (pl) |
| DK (4) | DK2440546T3 (pl) |
| ES (4) | ES2940885T3 (pl) |
| FI (3) | FI2440546T3 (pl) |
| HR (3) | HRP20240582T1 (pl) |
| HU (2) | HUE061262T2 (pl) |
| LT (1) | LT2440547T (pl) |
| MX (10) | MX373120B (pl) |
| PL (4) | PL2440547T3 (pl) |
| PT (4) | PT2440547T (pl) |
| RU (1) | RU2567752C2 (pl) |
| SI (1) | SI2440547T1 (pl) |
| TR (1) | TR201910781T4 (pl) |
| WO (3) | WO2010143169A2 (pl) |
| ZA (2) | ZA201109032B (pl) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
| KR20120051643A (ko) * | 2009-06-12 | 2012-05-22 | 쏘시에떼 스플리코 | 조기 노화, 구체적으로 조로증을 치료하는데 유용한 화합물 |
| HRP20191460T1 (hr) * | 2009-06-12 | 2019-11-15 | Abivax | Spojevi korisni za liječenje raka |
| MX2012002274A (es) | 2009-09-03 | 2012-09-07 | Bioenergenix | Compuestos heterociclicos para la inhibicion de pask. |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| EP2465502A1 (en) * | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| CN103391932B (zh) | 2011-01-05 | 2015-10-14 | 拜奥埃内杰尼克斯公司 | 用于抑制pask的杂环化合物 |
| AU2012223232B2 (en) | 2011-03-02 | 2017-05-25 | Bioenergenix | Heterocyclic compounds for the inhibition of PASK |
| US8916561B2 (en) | 2011-03-02 | 2014-12-23 | Bioenergenix, Llc | Substituted quinoxaline compounds for the inhibition of PASK |
| GB201118652D0 (en) * | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| FR2987627B1 (fr) | 2012-03-05 | 2016-03-18 | Splicos | Utilisation de rbm39 comme biomarqueur |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| US20150133450A1 (en) * | 2012-06-20 | 2015-05-14 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
| US9145411B2 (en) | 2012-08-02 | 2015-09-29 | Asana Biosciences, Llc | Substituted amino-pyrimidine derivatives |
| WO2014028479A1 (en) | 2012-08-13 | 2014-02-20 | Envoy Therapeutics, Inc. | Quinoxaline derivatives as gpr6 modulators |
| JP2014237624A (ja) * | 2012-10-23 | 2014-12-18 | 日本曹達株式会社 | ピリジン化合物またはその塩、有害生物防除剤、殺虫剤または殺ダニ剤、および外部寄生虫防除剤 |
| WO2014081953A1 (en) | 2012-11-21 | 2014-05-30 | Richard David J | Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives |
| GB201301571D0 (en) * | 2012-11-27 | 2013-03-13 | Fundanci N Pedro Barri De La Maza | Product and use |
| US20140194465A1 (en) * | 2013-01-04 | 2014-07-10 | Novarx Corporation | Compositions for treatment of cancer |
| EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| JP6895251B2 (ja) | 2013-07-05 | 2021-06-30 | アビバックス | レトロウイルスにより引き起こされる疾患を処理する為に有用な化合物 |
| WO2015005491A1 (ja) | 2013-07-12 | 2015-01-15 | 国立大学法人京都大学 | 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法 |
| US10732182B2 (en) | 2013-08-01 | 2020-08-04 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
| EP3063302B1 (en) | 2013-10-30 | 2019-12-04 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
| JO3466B1 (ar) | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
| US10179783B2 (en) | 2014-02-14 | 2019-01-15 | Taketa Pharmaceutical Company Limited | Tetrahydropyridopyrazines as modulators of GPR6 |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| JP6980385B2 (ja) | 2014-03-26 | 2021-12-15 | アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited | Ｆｇｆｒ阻害剤とｉｇｆ１ｒ阻害剤の組合せ |
| MA55696A (fr) | 2014-03-26 | 2022-02-23 | Astex Therapeutics Ltd | Combinaisons |
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP2975034A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
| CN107208066B (zh) | 2015-01-30 | 2022-09-30 | 国家科学研究中心 | Δ133P53β和Δ133P53γ同种型是癌症干细胞的生物标记物 |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| EP3059591A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Methods for screening compounds for treating or preventing a viral infection or a virus-related condition |
| EP3058940A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
| EP3059236A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| HRP20220012T1 (hr) | 2015-09-23 | 2022-04-01 | Janssen Pharmaceutica Nv | Bi-heteroaril supstituirani 1,4-benzodiazepini i njihova upotreba za liječenje raka |
| BR112018005637B1 (pt) | 2015-09-23 | 2023-11-28 | Janssen Pharmaceutica Nv | Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos |
| EP3390378B1 (en) * | 2015-12-17 | 2022-03-30 | AlonBio Ltd. | Small molecules against cancer |
| KR102828755B1 (ko) | 2015-12-17 | 2025-07-03 | 바이오카인 테라퓨틱스 리미티드 | 케모카인 활성 및/또는 암세포 성장 억제용 저분자 |
| AU2017216212B2 (en) * | 2016-02-03 | 2020-12-24 | Janssen Pharmaceutica Nv | Tau PET imaging ligands |
| EP3429998B1 (en) | 2016-03-18 | 2021-09-01 | ratiopharm GmbH | Process for preparing quinolin-2-yl-phenylamine derivatives and their salts |
| EP3484528B1 (en) | 2016-07-18 | 2020-11-25 | Janssen Pharmaceutica NV | Tau pet imaging ligands |
| AR112027A1 (es) * | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
| WO2019002228A1 (en) | 2017-06-26 | 2019-01-03 | Institut Pasteur | TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD |
| CN111032629A (zh) | 2017-08-29 | 2020-04-17 | 朱拉蓬基金会 | 喹啉和萘啶的衍生物和组合物 |
| US20200039989A1 (en) * | 2018-03-01 | 2020-02-06 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of dyrk/clk and uses thereof |
| WO2019186277A1 (en) | 2018-03-28 | 2019-10-03 | Institut Pasteur | Ultrasensitive hiv-1 p24 detection assay |
| EP3594205A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
| EP3594206A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| EP3669874A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of cancer |
| EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
| WO2020128033A1 (en) | 2018-12-20 | 2020-06-25 | Institut Pasteur | Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells |
| WO2020230144A1 (en) | 2019-05-15 | 2020-11-19 | Biokine Therapeutics Ltd. | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death |
| EP3858336A1 (en) | 2020-01-31 | 2021-08-04 | Abivax | Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
| EP3858815A1 (en) | 2020-01-31 | 2021-08-04 | Abivax | Co-crystals and salts of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
| AU2021213321A1 (en) * | 2020-01-31 | 2022-08-11 | Abivax | Amorphous solid dispersion of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
| WO2021186053A1 (en) | 2020-03-20 | 2021-09-23 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| RS66978B1 (sr) | 2020-07-02 | 2025-07-31 | Incyte Corp | Triciklična jedinjenja uree kao inhibitori jak2 v617f |
| WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| WO2022182839A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| EP4063351A1 (en) | 2021-03-26 | 2022-09-28 | Abivax | Preparation method of quinoline derivative compounds |
| JP2024519993A (ja) | 2021-05-27 | 2024-05-21 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | キノリンアミン系化合物、その調製方法及びその医薬的応用 |
| KR20230072900A (ko) | 2021-11-18 | 2023-05-25 | 동우 화인켐 주식회사 | 마이크로 led 구조체 및 이의 제조방법 |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| WO2023138657A1 (zh) * | 2022-01-24 | 2023-07-27 | 江苏恒瑞医药股份有限公司 | 喹啉胺类化合物、其制备方法及其在医药上的应用 |
| EP4215196A1 (en) | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
| KR20240163688A (ko) | 2022-03-17 | 2024-11-19 | 인사이트 코포레이션 | Jak2 v617f 억제제로서의 삼환계 우레아 화합물 |
| KR20250112264A (ko) | 2022-11-25 | 2025-07-23 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 퀴놀린아민계 화합물의 결정형 및 이의 제조 방법 |
| WO2025027388A1 (en) | 2023-08-01 | 2025-02-06 | Abivax | Obefazimod for treatment of ulcerative colitis |
| WO2025045123A1 (zh) * | 2023-08-30 | 2025-03-06 | 江苏正大丰海制药有限公司 | 用于调节微小rna-124活性的化合物 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR400973A (fr) | 1909-03-19 | 1909-08-13 | Jean Victor Massillon | Nouveau sertisseur à main pour la fabrication des cartouches |
| GB585362A (en) | 1944-08-31 | 1947-02-05 | Francis Henry Swinden Curd | New heterocyclic compounds |
| BE486034A (pl) | 1947-11-28 | |||
| DE958647C (de) | 1952-12-28 | 1957-02-21 | Hoechst Ag | Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen |
| FR2387229A1 (fr) | 1977-04-13 | 1978-11-10 | Anvar | Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
| FR2436786A1 (fr) | 1978-09-21 | 1980-04-18 | Anvar | Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments |
| FR2627493B1 (fr) * | 1988-02-23 | 1991-10-31 | Sanofi Sa | Procede de preparation de derives d'isoquinoleine |
| FR2645861A1 (fr) * | 1989-04-17 | 1990-10-19 | Inst Nat Sante Rech Med | Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| DE60008509T2 (de) * | 1999-04-05 | 2004-12-16 | City Of Hope, Duarte | Neue Hemmer von fortgeschrittenen Glykosilierungsendprodukten (AGEs) |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| DE10013318A1 (de) * | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
| JP4223287B2 (ja) | 2001-01-22 | 2009-02-12 | メモリー・ファーマスーティカルズ・コーポレーション | 新規な化合物及び製薬上許容し得るそれらの塩並びにそれらを用いた薬剤組成物 |
| PL375552A1 (pl) | 2002-05-22 | 2005-11-28 | Amgen Inc. | Ligandy receptora waniloidowego oraz ich medycznezastosowania |
| AU2002950217A0 (en) * | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| US7405230B2 (en) * | 2002-07-19 | 2008-07-29 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs |
| FR2849474B3 (fr) | 2002-12-27 | 2004-12-03 | Olivier Jean Noel Juin | Installation de transformation de l'energie cinetique d'un fluide en energie electrique |
| WO2004078731A1 (en) | 2003-03-06 | 2004-09-16 | 'chemical Diversity Research Institute', Ltd. | Quinoline-carboxylic acids and the derivatives thereof, a focused library |
| CA2518398A1 (en) | 2003-03-10 | 2004-09-23 | Schering Corporation | Heterocyclic kinase inhibitors: methods of use and synthesis |
| FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| FR2859475A1 (fr) | 2003-09-04 | 2005-03-11 | Centre Nat Rech Scient | Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| US20050084835A1 (en) * | 2003-10-16 | 2005-04-21 | The Singing Machine Company, Inc. | Karaoke system with built-in camera |
| BRPI0416692A (pt) * | 2003-11-19 | 2007-01-30 | Array Biopharma Inc | inibidores heterocìclicos de mek e métodos de emprego destes |
| JP2008519814A (ja) | 2004-11-12 | 2008-06-12 | ガラパゴス・ナムローゼ・フェンノートシャップ | プロテインキナーゼ酵素の活性部位と結合する窒素複素環式芳香族化合物 |
| EP1853265B1 (en) | 2005-01-28 | 2016-01-27 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Farnesyltransferase inhibitors for use in the treatment of laminopathies, cellular aging and atherosclerosis |
| WO2007000876A1 (ja) | 2005-06-29 | 2007-01-04 | Adeka Corporation | 樹脂添加剤組成物及びその樹脂組成物 |
| FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
| WO2008008234A1 (en) * | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
| EA200900959A1 (ru) * | 2007-01-19 | 2010-02-26 | Арди Байосайенсиз, Инк. | Ингибиторы мек |
| FR2912745A1 (fr) * | 2007-02-19 | 2008-08-22 | Centre Nat Rech Scient | Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant |
| CA2681481A1 (en) * | 2007-03-16 | 2008-09-25 | Mount Sinai School Of Medicine | Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction |
| DE112008001206B4 (de) | 2007-05-17 | 2019-01-31 | Lg Chem. Ltd. | Neue Anthrazen-Derivate und organische elektronische Vorrichtung, die diese verwendet |
| UY31272A1 (es) * | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| EP2184990A4 (en) | 2007-08-15 | 2011-10-19 | Memory Pharm Corp | 3'-SUBSTITUTED COMPOUNDS WITH 5-HT6 RECEPTOR AFFINITY |
| WO2009029617A1 (en) * | 2007-08-27 | 2009-03-05 | Kalypsys, Inc. | Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors |
| KR100974562B1 (ko) * | 2007-12-31 | 2010-08-06 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 발광재료로서 채용하고있는 유기 발광 소자 |
| FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
| EP2384337A1 (en) * | 2009-01-05 | 2011-11-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants |
| CA2744670C (en) * | 2009-01-06 | 2018-05-15 | Ziad Mallat | A b cell depleting agent for the treatment of atherosclerosis |
| WO2010079123A2 (en) * | 2009-01-06 | 2010-07-15 | Dsm Ip Assets B.V. | Process for resveratrol intermediate |
| EP2266972A1 (en) | 2009-06-12 | 2010-12-29 | Splicos | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
| KR20120051643A (ko) * | 2009-06-12 | 2012-05-22 | 쏘시에떼 스플리코 | 조기 노화, 구체적으로 조로증을 치료하는데 유용한 화합물 |
| HRP20191460T1 (hr) | 2009-06-12 | 2019-11-15 | Abivax | Spojevi korisni za liječenje raka |
| US8962583B2 (en) | 2009-06-25 | 2015-02-24 | The Brigham And Women's Hospital, Inc. | Treatment of inflammatory diseases using miR-124 |
| EP2465502A1 (en) | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| JP2016504268A (ja) | 2012-10-04 | 2016-02-12 | オヤジェン インコーポレイテッドＯｙａＧｅｎ， Ｉｎｃ． | Ｖｉｆの自己会合を撹乱する抗ｈｉｖ剤としての小分子及びその使用方法 |
| EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| JP2015120566A (ja) * | 2013-12-20 | 2015-07-02 | ニチユ三菱フォークリフト株式会社 | 荷役車両 |
-
2010
- 2010-06-14 KR KR1020127000914A patent/KR20120051643A/ko not_active Ceased
- 2010-06-14 PT PT107574741T patent/PT2440547T/pt unknown
- 2010-06-14 HU HUE10757474A patent/HUE061262T2/hu unknown
- 2010-06-14 BR BR122019013687A patent/BR122019013687B1/pt active IP Right Grant
- 2010-06-14 CA CA2764024A patent/CA2764024C/en active Active
- 2010-06-14 PT PT107283699T patent/PT2440546T/pt unknown
- 2010-06-14 CN CN201710122014.4A patent/CN106905232B/zh active Active
- 2010-06-14 CN CN201080032036.8A patent/CN102574835B/zh active Active
- 2010-06-14 CN CN201080032045.7A patent/CN102625804B/zh active Active
- 2010-06-14 WO PCT/IB2010/052651 patent/WO2010143169A2/en not_active Ceased
- 2010-06-14 KR KR1020197004607A patent/KR102016892B1/ko active Active
- 2010-06-14 DK DK10728369.9T patent/DK2440546T3/da active
- 2010-06-14 HR HRP20240582TT patent/HRP20240582T1/hr unknown
- 2010-06-14 KR KR1020197004608A patent/KR102016893B1/ko active Active
- 2010-06-14 BR BRPI1010772A patent/BRPI1010772B8/pt active IP Right Grant
- 2010-06-14 EP EP10728368.1A patent/EP2440545B1/en active Active
- 2010-06-14 WO PCT/IB2010/052650 patent/WO2010143168A2/en not_active Ceased
- 2010-06-14 MX MX2018009425A patent/MX373120B/es unknown
- 2010-06-14 CN CN201710158474.2A patent/CN106928194B/zh active Active
- 2010-06-14 TR TR2019/10781T patent/TR201910781T4/tr unknown
- 2010-06-14 CN CN201410106644.9A patent/CN103948594B/zh active Active
- 2010-06-14 EP EP22193611.5A patent/EP4198022A1/en active Pending
- 2010-06-14 KR KR1020187025623A patent/KR101982461B1/ko active Active
- 2010-06-14 CA CA3070823A patent/CA3070823C/en active Active
- 2010-06-14 CA CA2764026A patent/CA2764026C/en active Active
- 2010-06-14 HU HUE10728368A patent/HUE045548T2/hu unknown
- 2010-06-14 KR KR1020127000916A patent/KR101769616B1/ko active Active
- 2010-06-14 KR KR1020197004605A patent/KR102016890B1/ko active Active
- 2010-06-14 MX MX2016007353A patent/MX367601B/es unknown
- 2010-06-14 PL PL10757474.1T patent/PL2440547T3/pl unknown
- 2010-06-14 MX MX2016003039A patent/MX359575B/es unknown
- 2010-06-14 KR KR1020187025626A patent/KR101982463B1/ko active Active
- 2010-06-14 MX MX2015016293A patent/MX364989B/es unknown
- 2010-06-14 HR HRP20230248TT patent/HRP20230248T1/hr unknown
- 2010-06-14 CU CUP2011000229A patent/CU24124B1/es active IP Right Grant
- 2010-06-14 ES ES10728369T patent/ES2940885T3/es active Active
- 2010-06-14 HR HRP20230143TT patent/HRP20230143T1/hr unknown
- 2010-06-14 KR KR1020127000915A patent/KR101789275B1/ko active Active
- 2010-06-14 FI FIEP10728369.9T patent/FI2440546T3/fi active
- 2010-06-14 DK DK10728368.1T patent/DK2440545T3/da active
- 2010-06-14 EP EP19157827.7A patent/EP3517534B1/en active Active
- 2010-06-14 MX MX2011013120A patent/MX338823B/es active IP Right Grant
- 2010-06-14 CU CUP2015000024A patent/CU24245B1/es unknown
- 2010-06-14 MX MX2015016292A patent/MX364280B/es unknown
- 2010-06-14 FI FIEP10757474.1T patent/FI2440547T3/fi active
- 2010-06-14 JP JP2012514585A patent/JP6041671B2/ja active Active
- 2010-06-14 MX MX2011013122A patent/MX340095B/es active IP Right Grant
- 2010-06-14 SI SI201032127T patent/SI2440547T1/sl unknown
- 2010-06-14 US US13/377,760 patent/US9145367B2/en active Active
- 2010-06-14 ES ES19157827T patent/ES2985082T3/es active Active
- 2010-06-14 BR BRPI1012892A patent/BRPI1012892B8/pt active IP Right Grant
- 2010-06-14 KR KR1020197004606A patent/KR102016891B1/ko active Active
- 2010-06-14 KR KR1020187025625A patent/KR101982462B1/ko active Active
- 2010-06-14 US US13/377,745 patent/US20120277230A1/en not_active Abandoned
- 2010-06-14 AU AU2010258294A patent/AU2010258294B2/en active Active
- 2010-06-14 PT PT191578277T patent/PT3517534T/pt unknown
- 2010-06-14 CN CN201080032055.0A patent/CN102596935B/zh active Active
- 2010-06-14 MX MX2011013119A patent/MX353776B/es active IP Right Grant
- 2010-06-14 DK DK19157827.7T patent/DK3517534T3/da active
- 2010-06-14 FI FIEP19157827.7T patent/FI3517534T3/fi active
- 2010-06-14 AU AU2010258295A patent/AU2010258295B2/en active Active
- 2010-06-14 ES ES10757474T patent/ES2938532T3/es active Active
- 2010-06-14 EP EP10728369.9A patent/EP2440546B1/en active Active
- 2010-06-14 JP JP2012514586A patent/JP5826745B2/ja active Active
- 2010-06-14 CU CU2011000230A patent/CU24093B1/es active IP Right Grant
- 2010-06-14 AU AU2010258214A patent/AU2010258214B2/en active Active
- 2010-06-14 ES ES10728368T patent/ES2736198T3/es active Active
- 2010-06-14 CN CN201910120757.7A patent/CN109776496B/zh active Active
- 2010-06-14 CN CN201510023124.6A patent/CN104844570B/zh active Active
- 2010-06-14 LT LTEPPCT/IB2010/052651T patent/LT2440547T/lt unknown
- 2010-06-14 DK DK10757474.1T patent/DK2440547T3/da active
- 2010-06-14 KR KR1020177021820A patent/KR101863021B1/ko active Active
- 2010-06-14 MX MX2015016290A patent/MX364282B/es unknown
- 2010-06-14 PL PL19157827.7T patent/PL3517534T3/pl unknown
- 2010-06-14 CN CN201510023109.1A patent/CN104844510B/zh active Active
- 2010-06-14 US US13/377,753 patent/US20120329796A1/en not_active Abandoned
- 2010-06-14 CN CN201710158473.8A patent/CN106928205B/zh active Active
- 2010-06-14 EP EP10757474.1A patent/EP2440547B1/en active Active
- 2010-06-14 PL PL10728368T patent/PL2440545T3/pl unknown
- 2010-06-14 EP EP19157824.4A patent/EP3521283B1/en active Active
- 2010-06-14 KR KR1020177031675A patent/KR101897221B1/ko active Active
- 2010-06-14 KR KR1020197004604A patent/KR102016889B1/ko active Active
- 2010-06-14 RU RU2011149571/04A patent/RU2567752C2/ru active
- 2010-06-14 CU CU2011000228A patent/CU24461B1/es unknown
- 2010-06-14 CN CN201510021597.2A patent/CN104945379B/zh active Active
- 2010-06-14 CA CA2965791A patent/CA2965791C/en active Active
- 2010-06-14 CN CN202110307700.5A patent/CN113004249A/zh active Pending
- 2010-06-14 BR BR122019013686-6A patent/BR122019013686B1/pt active IP Right Grant
- 2010-06-14 JP JP2012514587A patent/JP5905385B2/ja active Active
- 2010-06-14 PT PT10728368T patent/PT2440545T/pt unknown
- 2010-06-14 PL PL10728369.9T patent/PL2440546T3/pl unknown
- 2010-06-14 WO PCT/IB2010/052652 patent/WO2010143170A2/en not_active Ceased
- 2010-06-14 KR KR1020187025624A patent/KR101973348B1/ko active Active
- 2010-06-14 CA CA2764027A patent/CA2764027C/en active Active
- 2010-06-14 CN CN201510020820.1A patent/CN104945378B/zh active Active
- 2010-06-14 MX MX2015016291A patent/MX364279B/es unknown
- 2010-06-14 BR BRPI1010768A patent/BRPI1010768C8/pt active IP Right Grant
-
2011
- 2011-12-08 ZA ZA2011/09032A patent/ZA201109032B/en unknown
- 2011-12-08 ZA ZA2011/09031A patent/ZA201109031B/en unknown
-
2013
- 2013-11-22 US US14/087,762 patent/US9108919B2/en active Active
-
2014
- 2014-04-18 US US14/256,334 patent/US9908869B2/en active Active
-
2015
- 2015-04-27 JP JP2015090437A patent/JP2015155453A/ja active Pending
- 2015-06-15 JP JP2015120568A patent/JP6158251B2/ja active Active
- 2015-06-15 JP JP2015120566A patent/JP2015187150A/ja not_active Withdrawn
- 2015-06-15 JP JP2015120567A patent/JP6158250B2/ja active Active
- 2015-07-01 US US14/789,250 patent/US10017498B2/en active Active
- 2015-07-01 US US14/789,149 patent/US9637475B2/en active Active
-
2019
- 2019-10-18 JP JP2019191500A patent/JP7042245B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2440545T3 (pl) | Związki użyteczne do leczenia nowotworu | |
| IL229878A (en) | Cancer Treatment Compounds | |
| IL209895A0 (en) | Compounds for treating beta-amyloidoses | |
| EP2424516A4 (en) | PENTAMIDINE COMBINATIONS FOR THE TREATMENT OF CANCER | |
| IL213398A0 (en) | Compounds for treating cancer | |
| IL213761A0 (en) | Novel ortho-aminoamides for the treatment of cancer | |
| ZA201203449B (en) | Sulfoxide derivatives for treating tumors | |
| GB0804496D0 (en) | Treating cancer | |
| EP2144888A4 (en) | METHODS OF TREATING CANCER | |
| PT2467140T (pt) | Lapatinib para tratamento do cancro | |
| LT2519231T (lt) | Proteosomų inhibitoriai vėžio gydymui | |
| GB0707556D0 (en) | Treatment for cancer | |
| ZA201201894B (en) | Pharmaceutical combination for treating tumor | |
| EP2307573A4 (en) | METHODS FOR SCREENING COMPOUNDS FOR TREATING CANCER | |
| GB0914322D0 (en) | Compounds for treating cancer | |
| GB0908537D0 (en) | Compositions for treating tumours | |
| GB0901497D0 (en) | Compound for therapy | |
| GB0914441D0 (en) | Compound for therapy | |
| GB0903080D0 (en) | Compound for therapy | |
| GB0814469D0 (en) | Treatment for tumours | |
| GB0903137D0 (en) | Treatment for tumas |